Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  BioInvent International AB    BINV   SE0000789711

BIOINVENT INTERNATIONAL AB

(BINV)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
07/12/2019 07/15/2019 07/16/2019 07/17/2019 07/18/2019 Date
1.588(c) 1.578(c) 1.712(c) 1.62(c) 1.638 Last
3 865 725 3 769 612 8 909 988 4 020 504 307 700 Volume
+0.76% -0.63% +8.49% -5.37% +1.11% Change
More quotes
Financials (SEK)
Sales 2019 68,3 M
EBIT 2019 -122 M
Net income 2019 -122 M
Finance 2019 170 M
Yield 2019 -
Sales 2020 345 M
EBIT 2020 143 M
Net income 2020 143 M
Finance 2020 107 M
Yield 2020 -
P/E ratio 2019 -6,63x
P/E ratio 2020 5,66x
EV / Sales2019 9,42x
EV / Sales2020 2,05x
Capitalization 813 M
More Financials
Company
BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human... 
More about the company
Latest news on BIOINVENT INTERNATIONAL AB
07/02BIOINVENT INTERNATIONAL : receives IND approval for Phase I/IIa trial of anti-Fc..
PU
06/28BIOINVENT INTERNATIONAL : Change in the number of shares and votes in BioInvent ..
PU
06/13BIOINVENT INTERNATIONAL : Publishes First Clinical Data From BI-1206 Phase l/lla..
AQ
06/03BIOINVENT INTERNATIONAL : submits IND for Phase I/IIa trial of anti-FcγRII..
PU
05/22BIOINVENT INTERNATIONAL : BioInvent Interim Report January 1 – March 31, 2..
PU
04/30BIOINVENT INTERNATIONAL : Change in the number of shares and votes in BioInvent ..
PU
04/26BIOINVENT INTERNATIONAL : BioInvent receives €0.75 million milestone under Mitsu..
PU
04/25BIOINVENT INTERNATIONAL : Resolutions at BioInvent's Annual General Meeting 2019
PU
04/04BIOINVENT INTERNATIONAL : partner Oxurion announces full enrollment of its Phase..
PU
04/03BIOINVENT INTERNATIONAL : Annual Report 2018
PU
More news
Analyst Recommendations on BIOINVENT INTERNATIONAL AB
More recommendations
Sector news : Bio Therapeutic Drugs
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Bio Therapeutic Drugs
Chart BIOINVENT INTERNATIONAL AB
Duration : Period :
BioInvent International AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOINVENT INTERNATIONAL AB
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 3,94  SEK
Last Close Price 1,62  SEK
Spread / Highest target 143%
Spread / Average Target 143%
Spread / Lowest Target 143%
EPS Revisions
Managers
NameTitle
Martin Welschof President & Chief Executive Officer
Leonard Kruimer Chairman
Kristoffer Rudenholm Hansson Vice President-Technical Operations
Stefan Ericsson Chief Financial Officer
Björn Frendéus Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOINVENT INTERNATIONAL AB-14.60%87
GILEAD SCIENCES6.99%84 164
VERTEX PHARMACEUTICALS6.90%45 080
REGENERON PHARMACEUTICALS-19.83%31 857
SAREPTA THERAPEUTICS INC40.43%11 437
GENMAB14.24%11 148